Also trades as: DMRA (NASDAQ) · $vol 8M
GLTO NASDAQ
Galecto, Inc.
1W: +4.2%
1M: -9.0%
3M: -21.1%
YTD: +10.2%
1Y: +735.1%
3Y: -50.9%
5Y: -80.9%
$24.48
+0.44 (+1.83%)
Weekly Expected Move ±7.4%
$21
$23
$25
$26
$28
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$38.4M
52W Range2.01-38.325
Volume116,894
Avg Volume224,729
Beta1.57
Dividend—
Analyst Ratings
Company Info
CEOLori C. Firmani
Employees5
SectorHealthcare
IndustryBiotechnology
IPO Date2020-10-29
Websitegalecto.com
75 State Street
Boston, MA 02109
US
Boston, MA 02109
US
457 070 5210
About Galecto, Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
Latest News
Galecto, Inc. (NASDAQ:GLTO) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Galecto to Participate in Leerink Partners 2026 Global Healthcare Conference
Galecto, Inc. (NASDAQ:GLTO) Short Interest Up 86.6% in February
Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million
Galecto Announces Pricing of $275 Million Underwritten Public Offering
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bruno Julianne | M-Exempt | 129,000 | — | 2026-02-09 |
| Bruno Julianne | M-Exempt | 129 | — | 2026-02-09 |
| Fairmount Funds Mana | M-Exempt | 5,809,000 | — | 2026-02-09 |
| Fairmount Funds Mana | M-Exempt | 2,904,000 | — | 2026-02-09 |
| Fairmount Funds Mana | M-Exempt | 5,809 | — | 2026-02-09 |